6 enrolling by invitation. 6 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Enrolling by invitation 6 |
| Phase 2 | 4 | Enrolling by invitation 4 |
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
| Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients venetoclax - Acute Promyelocytic Leukemia | Phase 2 / Phase 3 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 98 | 2023-08-01 | 2024-08-09 |
| Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome Fludarabine and Busulfan, Fludarabine and Melphalan - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS) | Phase 3 | Enrolling by invitation | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 200 | 2023-02-15 | 2025-02-10 |
| A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML. High dose Cytarabine, Cytarabine, Hign dose Daunorubicin - Acute Myeloid Leukemia | Phase 3 | Enrolling by invitation | Asan Medical Center | 380 | 2018-03-01 | 2025-03-17 |
Leukemia, Myeloid, Acute (5) · Leukemia, Promyelocytic, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasm, Residual (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Leukemia (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Bone Marrow Diseases (1) · Leukemia, Myeloid, Acute (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cytarabine (2) · Induction Chemotherapy (2) · Opiate Substitution Treatment (2) · Azacitidine (1) · Busulfan (1) · Melphalan (1) · fludarabine (1) · fludarabine phosphate (1) · venetoclax (1)
First Affiliated Hospital of Zhejiang University (2) · Asan Medical Center (1) · Guangdong Second Provincial General Hospital (1) · The First Affiliated Hospital of Soochow University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (5) · South Korea (1)
Je-Hwan Lee, MD (1) · Linghui Xia, Professor (1)